Remedium Lifecare Ltd.
Bombay Stock ExchangeTotal Valuation
Remedium Lifecare Ltd. carries a market capitalization of 749.69M, placing it among publicly traded companies globally. Its enterprise value stands at 690.30M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 749.69M |
| Enterprise Value | 690.30M |
Valuation Ratios
Remedium Lifecare Ltd. trades at a trailing price-to-earnings ratio of 13.42.
| PE Ratio | 13.42 |
| PS Ratio | 0.16 |
| PB Ratio | N/A |
| P/TBV Ratio | N/A |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Remedium Lifecare Ltd. trades at an EV/EBITDA multiple of 25.34 and an EV/FCF ratio of 13.80. The EV/Sales ratio of 0.16 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 25.34 provides insight into valuation relative to core operating earnings.
| EV / Sales | 0.16 |
| EV / EBITDA | 25.34 |
| EV / EBIT | 25.34 |
| EV / FCF | 13.80 |
Financial Position
Remedium Lifecare Ltd. maintains a current ratio of 2.05, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 497.74, indicating elevated leverage, while an interest coverage ratio of 0.36 demonstrates limited ability to service its debt obligations.
| Current Ratio | 2.05 |
| Quick Ratio | 0.00 |
| Debt / Equity | 497.74 |
| Debt / EBITDA | N/A |
| Interest Coverage | 0.36 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | N/A |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | -19.30 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
Over the trailing twelve months, Remedium Lifecare Ltd. has paid 26.88M in income taxes, reflecting an effective tax rate of 34.33.
| Income Tax | 26.88M |
| Effective Tax Rate | 34.33 |
Stock Price Statistics
Remedium Lifecare Ltd.'s stock has declined approximately -76.38889% over the past 52 weeks. The 50-day moving average sits at 0.88, while the 200-day moving average is 1.27.
| Beta (5Y) | N/A |
| 52-Week Price Change | -76.38889% |
| 50-Day Moving Average | 0.88 |
| 200-Day Moving Average | 1.27 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Remedium Lifecare Ltd. generated 4.41B in revenue and converted that into 51.42M in net income, yielding earnings per share of 0.07. EBITDA reached 27.24M, while operating income came in at 27.24M.
| Revenue | 4.41B |
| Gross Profit | 110.33M |
| Operating Income | 27.24M |
| Pretax Income | 78.30M |
| Net Income | 51.42M |
| EBITDA | 27.24M |
| EBIT | 27.24M |
| Earnings Per Share (EPS) | 0.07 |
Margins
Remedium Lifecare Ltd. operates with a gross margin of 2.50, reflecting its pricing power and cost economics. The operating margin of 0.62 and net profit margin of 1.17 provide insight into operational efficiency.
| Gross Margin | 2.50 |
| Operating Margin | 0.62 |
| Pretax Margin | 1.78 |
| Profit Margin | 1.17 |
| EBITDA Margin | 0.62 |
Stock Splits
Remedium Lifecare Ltd.'s most recent stock split took place on July 5, 2024 with a 1:4 split ratio.
| Last Split Date | 7/5/2024 |
| Split Ratio | 1:4 |
Scores
Remedium Lifecare Ltd. posts an Altman Z-Score of 2.05, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.05 |